cyproheptadine has been researched along with 1-hexadecyl-2-acetyl-glycero-3-phosphocholine in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (14.29) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 5 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, M; Imai, Y; Oh-ishi, S | 1 |
| Arimura, A; Harada, M; Nagata, M; Nakamura, K; Takeuchi, M; Watanabe, A | 1 |
| Balsa, D; Ferrando, R; Forn, J; García-Rafanell, J; Giral, M; Merlos, M; Puigdemont, A; Queralt, M | 1 |
| Akbaş, N; Barlas, A; Küçükhüseyin, C; Oncel, H; Payat, M; Silan, C | 1 |
| Harada, M; Kimura, S; Nagata, M; Takeuchi, M; Watanabe, A | 1 |
| Makiyama, Y; Mitsui, Y; Tanaka, Y | 1 |
| García-Rafanell, J; Izquierdo, I; Merlos, M | 1 |
| Dumur, JP; Izquierdo, I; Pérez, I; Saint-Martin, F | 1 |
| Barbanoj, MJ; García-Gea, C; Izquierdo, I; Jané, F; Morte, A; Pérez, I | 1 |
| Arnaiz, E; Borja, J; Conde, J; De Molina, M; Izquierdo, I; Martí-Guadaño, E; Martínez-Cócera, C; Pérez, I; Pola, J | 1 |
| Keam, SJ; Plosker, GL | 1 |
| He, JL; Lu, J; Xu, GL; Yu, SQ; Zhang, LL; Zhou, M | 1 |
| Bachert, C; Bousquet, J; Canonica, WG; Gimenez-Arnau, A; Kowalski, ML; Martí-Guadaño, E; Maurer, M; Mullol, J; Picado, C; Scadding, G; Van Cauwenberge, P | 1 |
| Fan, G; Hong, Z; Wei, H; Wen, J; Wu, Y | 1 |
| Fité-Mora, R | 1 |
| Cassano, N; Delle Donne, P; Di Leo, E; Foti, C; Nettis, E; Vacca, A; Vena, GA | 1 |
| Borja, J; Fité, R | 1 |
| Ferrán, M; Giménez-Arnau, A; Izquierdo, I; Maurer, M; Metz, M; Scholz, E | 1 |
| Antonijoan, RM; Barbanoj, MJ; Donado, E; García, O; Gich, I; Izquierdo, I; Morganroth, J; Peña, J; Pérez, I; Solans, A | 1 |
| Church, MK | 1 |
| Maurer, M; Metz, M | 1 |
| He, S; Mo, YZ; Wei, JF; Wei, XL; Yang, H | 1 |
| Calogiuri, GF; Delle Donne, P; Di Leo, E; Ferrannini, A; Nettis, E; Vacca, A | 1 |
| Canonica, GW; Compalati, E | 1 |
| Fu, XM; Hu, ZW; Li, K; Li, Z; Lv, Q; Lv, XX; Wang, XX; Wang, ZY | 1 |
| Alevizos, M; Kalogeromitros, D; Karagkouni, A; Makris, M; Sismanopoulos, N; Theoharides, TC; Vasiadi, M | 1 |
| Bachert, C; Bousquet, J; Canonica, GW; Giménez-Arnau, A; Kowalski, ML; Maurer, M; Mullol, J; Ryan, D; Scadding, G; Simons, FE | 1 |
| Badyal, DK; Johnson, M; Kwatra, G; Thomas, EA | 1 |
| Bachert, C; González-Núñez, V; Mullol, J | 1 |
| Ferber, G; Fernandes, S; Izquierdo, I; Lorch, U; Santamaría, E; Täubel, J | 1 |
| Abdel-Hakeem, EA; Hafez, HM; Hassanein, H | 1 |
| Antonopoulou, S; Demopoulos, C; Theoharides, TC | 1 |
| Beyer, S; Burges, A; Chelariu-Raicu, A; Czogalla, B; Deuster, E; Hester, A; Hysenaj, I; Jeschke, U; Kahaly, M; Kolben, T; Kraus, F; Mahner, S; Mayr, D; Schmoeckel, E; Trillsch, F | 1 |
| Abdalla, AM; Abdelbaky, FAF; Abdelzaher, WY; Hafez, SMNA; Khalaf, HM; Welson, NN | 1 |
| Abdel Hafez, SMN; Abdel-Gaber, SA; Abdelmonaem, AA; Hafez, HM; Ibrahim, MA; Yehia Abdelzaher, W | 1 |
9 review(s) available for cyproheptadine and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
| Article | Year |
|---|---|
Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis.
Topics: Animals; Clinical Trials as Topic; Cyproheptadine; Dose-Response Relationship, Drug; Histamine H1 Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal | 2003 |
Rupatadine: a review of its use in the management of allergic disorders.
Topics: Adolescent; Adult; Aged; Animals; Anti-Allergic Agents; Cyproheptadine; Drug Interactions; Humans; Hypersensitivity; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria | 2007 |
Rupatadine in allergic rhinitis and chronic urticaria.
Topics: Adolescent; Animals; Anti-Allergic Agents; Child; Chronic Disease; Clinical Trials as Topic; Cyproheptadine; Dogs; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Treatment Outcome; Urticaria | 2008 |
Rupatadine for the treatment of allergic rhinitis and urticaria.
Topics: Anti-Allergic Agents; Chronic Disease; Cyproheptadine; Histamine H1 Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Treatment Outcome; Urticaria | 2011 |
Rupatadine for the treatment of urticaria.
Topics: Animals; Cyproheptadine; Histamine Antagonists; Humans; Platelet Activating Factor; Urticaria | 2013 |
Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis.
Topics: Conjunctivitis, Allergic; Cyproheptadine; Histamine Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Treatment Outcome; Urticaria | 2013 |
Update on rupatadine in the management of allergic disorders.
Topics: Cyproheptadine; Humans; Hypersensitivity; Platelet Activating Factor; Treatment Outcome | 2015 |
Rupatadine: global safety evaluation in allergic rhinitis and urticaria.
Topics: Animals; Anti-Allergic Agents; Blood-Brain Barrier; Cyproheptadine; Histamine H1 Antagonists; Humans; Platelet Activating Factor; Rhinitis, Allergic; Urticaria | 2016 |
COVID-19, microthromboses, inflammation, and platelet activating factor.
Topics: Antiviral Agents; Blood Platelets; COVID-19; Cyproheptadine; Disseminated Intravascular Coagulation; Gene Expression Regulation; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Lung; Luteolin; Mast Cells; Platelet Activating Factor; Pulmonary Embolism; Quercetin; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
7 trial(s) available for cyproheptadine and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
| Article | Year |
|---|---|
A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Histamine H1 Antagonists; Humans; Loratadine; Male; Middle Aged; Platelet Activating Factor; Probability; Reference Values; Rhinitis, Allergic, Seasonal; Severity of Illness Index; Treatment Outcome | 2004 |
Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers.
Topics: Adult; Analysis of Variance; Attention; Cross-Over Studies; Cyproheptadine; Decision Making; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Flicker Fusion; Follow-Up Studies; Histamine; Histamine H1 Antagonists; Humans; Hydroxyzine; Male; Motor Activity; Neuropsychological Tests; Pain Measurement; Platelet Activating Factor; Psychomotor Performance; Reaction Time; Self-Assessment; Skin Tests; Statistics, Nonparametric; Time Factors | 2004 |
Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Platelet Activating Factor; Rhinitis, Allergic, Seasonal; Treatment Outcome | 2005 |
Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria.
Topics: Adult; Cold Temperature; Cyproheptadine; Double-Blind Method; Environmental Exposure; Female; Histamine Antagonists; Humans; Male; Middle Aged; Platelet Activating Factor; Pruritus; Treatment Outcome; Urticaria | 2010 |
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
Topics: Adolescent; Adult; Anti-Allergic Agents; Cyproheptadine; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Platelet Activating Factor; Time Factors; Young Adult | 2010 |
Levocetirizine and rupatadine in chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Cetirizine; Child; Chronic Disease; Cyproheptadine; Female; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle Aged; Platelet Activating Factor; Quality of Life; Severity of Illness Index; Tumor Necrosis Factor-alpha; Urticaria; Young Adult | 2015 |
Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
Topics: Adult; Area Under Curve; Cognition; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Histamine Antagonists; Humans; Japan; Male; Placebos; Platelet Activating Factor | 2016 |
19 other study(ies) available for cyproheptadine and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
| Article | Year |
|---|---|
Involvement of platelet-activating factor in zymosan-induced rat pleurisy.
Topics: Animals; Cyproheptadine; Eosinophils; Inflammation; Leukocytes; Male; Mast Cells; Neutrophils; Platelet Activating Factor; Pleurisy; Pyridinium Compounds; Rabbits; Rats; Rats, Inbred Strains; Zymosan | 1991 |
Production of active and passive anaphylactic shock in the WBB6F1 mouse, a mast cell-deficient strain.
Topics: Anaphylaxis; Animals; Cyproheptadine; Female; Histamine; Immunization, Passive; Mast Cells; Mice; Mice, Mutant Strains; Phospholipid Ethers; Platelet Activating Factor; Serotonin | 1990 |
Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Topics: Administration, Oral; Animals; Azepines; Blood Pressure; Cyproheptadine; Dogs; Guinea Pigs; Histamine Antagonists; Male; Mice; Motor Activity; Platelet Activating Factor; Platelet Aggregation; Pyrilamine; Rabbits; Rats; Rats, Sprague-Dawley; Triazoles | 1997 |
On the mechanisms of adenosine induced pulmonary vasoconstriction in rats.
Topics: Adenosine; Adrenergic Antagonists; Animals; Cyclooxygenase Inhibitors; Cyproheptadine; Dihydroergotoxine; Endothelium, Vascular; Female; Flavonoids; Ginkgo biloba; In Vitro Techniques; Indomethacin; Male; Methylene Blue; Plant Extracts; Platelet Activating Factor; Pulmonary Artery; Purinergic P1 Receptor Antagonists; Purinergic P2 Receptor Antagonists; Quinidine; Rats; Rats, Sprague-Dawley; Theophylline; Vasoconstriction | 1997 |
Suppressive effects of antihistaminic and/or anti-PAF agents on passive anaphylactic shock in mice sensitized with allogeneic monoclonal IgE and IgG1 antibodies and hyperimmune serum.
Topics: Anaphylaxis; Animals; Antibodies, Monoclonal; Cattle; Cyproheptadine; Female; Histamine H1 Antagonists; Immunoglobulin E; Immunoglobulin G; Immunosuppressive Agents; Isoantibodies; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Piperazines; Platelet Activating Factor; Propranolol; Pyridinium Compounds; Serum Albumin, Bovine; Triprolidine | 1998 |
Anti-CD44 monoclonal antibody (IM7) induces murine systemic shock mediated by platelet activating factor.
Topics: Anaphylaxis; Animals; Anti-Allergic Agents; Antibodies, Monoclonal; Azepines; Capillary Permeability; Cyproheptadine; Diphenhydramine; Erythrocytes; Hyaluronan Receptors; Hypotension; Immunoglobulin Fab Fragments; Immunoglobulin G; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Platelet Activating Factor; Triazoles | 2002 |
[Protective effect of rupatadine against oleic acid-induced acute lung injury in rabbits].
Topics: Animals; Blood Gas Analysis; Bronchoalveolar Lavage Fluid; Cyproheptadine; Enzyme-Linked Immunosorbent Assay; Intercellular Adhesion Molecule-1; Interleukin-8; Lung; Male; Oleic Acid; Platelet Activating Factor; Protective Agents; Rabbits; Random Allocation; Respiratory Distress Syndrome | 2007 |
Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers.
Topics: Adult; Asian People; Calibration; Chromatography, Liquid; Cyproheptadine; Drug Stability; Female; Formates; Freezing; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Methanol; Molecular Structure; Platelet Activating Factor; Quality Control; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tablets; Tandem Mass Spectrometry; Time Factors; Water; Young Adult | 2009 |
Torsade de pointes associated with rupatadine.
Topics: Cyproheptadine; Histamine H1 Antagonists; Humans; Long QT Syndrome; Platelet Activating Factor; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Spain; Torsades de Pointes | 2009 |
Treatment of acquired cold urticaria with rupatadine.
Topics: Adult; Chronic Disease; Cold Temperature; Cyproheptadine; Female; Humans; Middle Aged; Platelet Activating Factor; Treatment Outcome; Urticaria | 2009 |
Rupatadine and heart rhythm disturbances.
Topics: Arrhythmias, Cardiac; Cyproheptadine; Humans; Platelet Activating Factor | 2010 |
Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males.
Topics: Administration, Oral; Adult; Area Under Curve; Cyproheptadine; Histamine; Histamine H1 Antagonists; Humans; Injections, Intradermal; Male; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Pruritus; Skin; Young Adult | 2010 |
Induction of mast-cell accumulation by promutoxin, an Arg-49 phospholipase A2.
Topics: Animals; Bothrops; Cell Adhesion Molecules; Cyproheptadine; Ginkgolides; Histamine; Histamine Release; Inflammation; Lactones; Male; Mast Cells; Mice; Mice, Inbred BALB C; Peritoneum; Phospholipases A2; Phospholipases A2, Secretory; Platelet Activating Factor; Reptilian Proteins; Snake Venoms; Terfenadine | 2013 |
Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents.
Topics: Animals; Cellular Senescence; Cyproheptadine; Lung; Male; Mice; Mice, Inbred C57BL; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Tumor Suppressor Protein p53 | 2013 |
Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor.
Topics: Anti-Allergic Agents; beta-N-Acetylhexosaminidases; Cell Line, Tumor; Cyproheptadine; Histamine; Humans; Interleukin-8; Mast Cells; Platelet Activating Factor; Substance P; Tumor Necrosis Factor-alpha | 2013 |
Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats.
Topics: Animals; Blood Glucose; Cyclin-Dependent Kinase Inhibitor p21; Cyproheptadine; Cystatin C; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Histamine Antagonists; Kidney; Male; Oxidative Stress; Platelet Activating Factor; Rats; Streptozocin; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2020 |
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyproheptadine; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Ovary; Platelet Activating Factor; Platelet Membrane Glycoproteins; Prognosis; Receptors, G-Protein-Coupled; Signal Transduction; Treatment Outcome | 2021 |
Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cyproheptadine; Fluorouracil; Heme Oxygenase-1; Liver; Male; Oxidative Stress; Platelet Activating Factor; Rats | 2022 |
Rupatadine ameliorated ulcerative colitis in rats via modulation of platelet-activatiweng factor/interleukin-6/vascular endothelial growth factor signalling pathway.
Topics: Acetic Acid; Animals; Antioxidants; Colitis, Ulcerative; Colon; Cyproheptadine; Histamine; Interleukin-6; Male; Platelet Activating Factor; Rats; Rats, Wistar; Signal Transduction; Vascular Endothelial Growth Factor A | 2022 |